Press Releases

epi in the news

Follow the link to read the announcement

May 17

Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CA​

May 9

Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test

May 8

Exosome Diagnostics Expands National Sales Team after Blockbuster Quarter with its Flagship Diagnostic, ExoDx® Prostate(IntelliScore) (EPI) Test

March 21, 2018

Exosome Diagnostics Appoints Accomplished Urologist, Grannum Sant, MD, FRCS, FACS, as Head of Medical Affairs

February 23. 2018

Exosome Diagnostics Expands its Coverage Reach for EPI to an Additional 82 Million Covered Lives in the United States

February 1, 2018

Exosome Diagnostics Significantly Expands Access and Coverage for its EPI Prostate Cancer Test through Agreement with FedMed​

January 25 2018

Exosome Diagnostics Executes Agreement with America’s Choice Provider Network Expanding Access and Coverage for EPI to 28 Million Member Network in the US

January 8, 2018

Exosome Diagnostics Announces Positive Coverage for EPI from Largest Payor in the Mid-Atlantic Region

January 4, 2018

Exosome Diagnostics Launches National Sales Team to Support Flagship ExoDx® Prostate(IntelliScore)

December 4, 2017

Exosome Diagnostics Executes Coverage Agreement for its EPI Test with Three Rivers Provider Network

November 27, 2017

Exosome Diagnostics Announces National Medicare Reimbursement Rate Set at $760 for its Prostate Cancer IntelliScore Test​

September 19, 2017

Exosome Diagnostics and Chesapeake Urology Partner to Evaluate Clinical Value of ExoDx® Prostate(IntelliScore) in First Study Under Novel Evidence Development Collaboration

April 26, 2017

American Medical Association (AMA) Grants Exosome Diagnostics a CPT PLA Specific to Its ExoDx®Prostate(IntelliScore) Test

September 13, 2016

Exosome Diagnostics Appoints Elizabeth Cormier-May as Head of Commercial Diagnostics

September 7, 2016

Exosome Diagnostics Announces Launch of ExoDx®Prostate(IntelliScore), a Completely Non-Invasive Liquid Biopsy Test to Help Rule Out High-Grade Prostate Cancer

April 12, 2016

Clinical Data for World’s First Truly Non-Invasive Prostate Cancer Test Published in JAMA Oncology

January 26, 2016

ExoDx™ Prostate(IntelliScore): A More Precise, Genetically Informed Prostate Cancer Test from a Simple Urine Sample

October 1, 2015

Exosome Diagnostics Announces Data Demonstrating ExoIntelliScore™ Prostate Accurately Predicted Gleason Score, Pathologic Stage and Tumor Volume in Patients with Prostate Cancer

September 21, 2015

Exosome Diagnostics Announces Publication of ExoIntelliScore™ Prostate Initial Clinical Study Positive Results

August 12, 2015

Exosome Diagnostics Launches CLIA-Certified Laboratory in Cambridge, Mass.

May 17, 2015

Exosome Diagnostics Announces Positive Results from Large Clinical Validation Study of Prostate Cancer Liquid Biopsy

February 26, 2015

Exosome Diagnostics Announces Positive Results from Initial Clinical Study of Novel Prostate Cancer Liquid Biopsy

exosome diagnostics in the news

Follow the link to read the announcement

June 25

Bio-Techne to Acquire Exosome Diagnostics, Inc.

June 13

Exosome Diagnostics Achieves ISO 13485:2016 Certification

May 22

Exosome Diagnostics Announces Bladder Cancer Surveillance Panel: The First Liquid Biopsy Designed Entirely By Artificial Intelligence (AI)​

Exosome Diagnostics and ExoDx, are registered and unregistered trademarks of Exosome Diagnostics, Inc.

BSI-Assurance-Mark-ISO-13485-KEYB